Ameriprise
RCEL icon

Ameriprise’s Avita Medical RCEL Stock Holding History

Ameriprise’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Sell
28,754
-368
-1% -$1.54K ﹤0.01% 3953
2025
Q4 		$100K Buy
29,122
+50
+0.2% +$200 ﹤0.01% 4004
2025
Q3 		$149K Sell
29,072
-203
-0.7% -$1.06K ﹤0.01% 3936
2025
Q2 		$155K Sell
29,275
-4,047
-12% -$29.4K ﹤0.01% 3848
2025
Q1 		$271K Sell
33,322
-14,271
-30% -$133K ﹤0.01% 3708
2024
Q4 		$609K Buy
47,593
+3,269
+7% +$38.6K ﹤0.01% 3446
2024
Q3 		$475K Buy
44,324
+670
+2% +$6.29K ﹤0.01% 3499
2024
Q2 		$346K Sell
43,654
-8,163
-16% -$77.6K ﹤0.01% 3549
2024
Q1 		$831K Sell
51,817
-46,865
-47% -$758K ﹤0.01% 3244
2023
Q4 		$1.35M Sell
98,682
-15,564
-14% -$178K ﹤0.01% 3068
2023
Q3 		$1.67M Sell
114,246
-256
-0.2% -$4.33K ﹤0.01% 2908
2023
Q2 		$1.95M Sell
114,502
-17,107
-13% -$251K ﹤0.01% 2887
2023
Q1 		$1.84M Sell
131,609
-16,343
-11% -$174K ﹤0.01% 2885
2022
Q4 		$976K Sell
147,952
-1,735
-1% -$10.4K ﹤0.01% 3138
2022
Q3 		$790K Sell
149,687
-4,270
-3% -$26.4K ﹤0.01% 3224
2022
Q2 		$731K Buy
153,957
+42,245
+38% +$261K ﹤0.01% 3245
2022
Q1 		$947K Buy
+111,712
New +$1.03M ﹤0.01% 3238

Other funds holding RCEL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ameriprise's RCEL Position: Q1 2026 in Review

Ameriprise reduced its Avita Medical (RCEL) stake by 1.3% in Q1 2026, selling an estimated $1.54K and leaving 28,754 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #3953.

Ameriprise first reported a position in RCEL in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.95M in Q2 2023. 79 funds tracked by Wall St. Rank hold RCEL as of Q1 2026.

  • Ameriprise held 28,754 shares of Avita Medical worth $106K as of Q1 2026.
  • Ameriprise sold 368 Avita Medical shares in Q1 2026, an estimated $1.54K.
  • Avita Medical made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3953 holding.
  • Ameriprise first reported a position in Avita Medical in Q1 2022 and has held it in 17 quarters since.
  • Ameriprise's Avita Medical position peaked at $1.95M in Q2 2023.
  • 79 funds tracked by Wall St. Rank held Avita Medical as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.